ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES

Similar documents
Atrial fibrillation and stroke. Isabelle C Van Gelder University Medical Center Groningen The Netherlands

Defining Sub-Clinical Atrial Fibrillation and its management

Subclinical AF: Implications of device based episodes

Diagnosing atrial fibrillation using implantable devices

Cryptogenic Stroke: The role of silent Atrial Fibrillation

Consensus document: Screening and Prevention of Atrial Fibrillation

Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University

Spontaneous Atrial Fibrillation and Noacs and Reversal agents

TOP 3: EMBRACE. Lucy Vieira MD FRCP Neurologist MUHC. N Engl J Med Volume 370(26): June 26, David J.

Fibrillazione Atriale Fattore di Rischio o Marker di Stroke: Implicazioni Per La Terapia

AF detection: What s new? Christopher B. Granger

ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ

Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation

Device detected AF and atrial high rate episodes

SUBCLINICAL ATRIAL FIBRILLATION IN PATIENTS WITH IMPLANTABLE DEVICEs ORAL ANTICOAGULANT THERAPY: TO GIVE OR NOT TO GIVE, THIS IS THE PROBLEM!!

What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen

Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients

Asymptomatic Atrial Fibrillation: Detection and Management. 18 December nd Annual Advances in Heart Disease Palace Hotel, San Francisco

Causal relationship between AF & stroke

Causal relationship between AF & stroke

Στυλιανός Τζέης MD, PhD, FESC

Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici?

Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use?

Seek and Ye Shall Find: Surprising Findings When Using the ILR-LINQ

Continuous ECG telemonitoring with implantable devices: the expected clinical benefits

Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος;

UTILITY OF THE IMPLANTABLE LOOP RECORDER

Fibrillazione atriale: è sempre necessario ricercarla, e come?

Fibrillazione atriale subclinica e rischio di ictus ischemico

Atrial fibrillation (AF) has been the. Subclinical Atrial Fibrillation, Embolic Risk, and Anticoagulant Treatment

Device Diagnostics and Stroke Prevention: State of the Art

Supplementary Online Content

Cryptogenic Stroke: What Don t We Know. Siddharth Sehgal, MD Medical Director, TMH Stroke Center Tallahassee Memorial Healthcare

Speakers. 2015, American Heart Association 1

Rebuttal. Jerónimo Farré MD 2010

POWERFUL CARDIAC MONITORING

Mohammad Zubaid, MB, ChB, FRCPC, FACC

Direct oral anticoagulants for Embolic Strokes of Undetermined Source? George Ntaios University of Thessaly, Larissa/Greece

Medicare Advantage Medical Policy

AF Detection During Drug Development: What Constitutes a Signal

National Medical Policy

2017 Cardiovascular Symposium CRYPTOGENIC STROKE: A CARDIOVASCULAR PERSPECTIVE DR. WILLIAM DIXON AND DR. VENKATA BAVAKATI SOUTHERN MEDICAL GROUP, P.A.

Controversies in Risk Stratification

ATRIAL FIBRILLATION: IS IT REALLY TYPE 2 DIABETES MASQUERADING AS CARDIAC MISFORTUNE?

True cryptogenic stroke

Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.

Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de

The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study

ESC Stockholm Arrhythmias & pacing

Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?

High Risk OSA n = 5,359

REVEAL AF IN YOUR CRYPTOGENIC STROKE PATIENTS

Management of atrial fibrillation in heart failure

pat hways Medtech innovation briefing Published: 16 February 2018 nice.org.uk/guidance/mib141

NT-proBNP For The Detection of Silent Paroxysmal Atrial Fibrillation In Patients With Recent Cerebral Ischemia results from the Find-AF trial

Why to monitor AF ablation success?

Management of Atrial Fibrillation. Leon Ptaszek, MD, PhD, FACC, FHRS 25 March 2018

IS ATRIAL FIBRILLATION THE NEXT TYPE 2 DIABETES?

Make the Connection A clinical compendium on the relationship between AF, stroke, and early intervention

Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015

What s new in my specialty?

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION

Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE

Post-ablation Management: Drug therapy, Anticoagulation and long-term Monitoring

How atrial fibrillation should be treated in the heart failure patient?

Management and Investigation of Ischemic Stroke By Etiology

Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland

AF monitoring and stroke: XPECT & REVEAL LINQ. Helmut Pürerfellner, Linz, Austria

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers

Management of Atrial Fibrillation in the Hospitalized Patient

Atrial fibrillation and mortality: where is the missing link? Isabelle C Van Gelder University Medical Center Groningen

Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, MD, FHRS

IS THERE A LINK BETWEEN ATRIAL FIBRILLATION AND MY STROKE? Finding answers about cryptogenic stroke

Atrial Fibrillation New Approaches, Techniques, and Technology

ECTOPIC BEATS: HOW MANY COUNT?

Cardiac Electrophysiology

La strategia diagnostica: il monitoraggio ecg prolungato. Michele Brignole

CRYPTOGENIC STROKE. Reveal LINQ TM THERAPY AWARENESS PRESENTATION

Fred Kusumoto Professor of Medicine

Atrial Fibrillation and Heart failure

Manuel Castella MD PhD Hospital Clínic, University of

Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation

Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry

Polypharmacy - arrhythmic risks in patients with heart failure

Atrial fibrillation and advanced age

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

A Streamlined Approach to Atrial Fibrillation Screening

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

PRO. HF treatment can reduce the risk of stroke. Wolfram Doehner, PD, PhD

Secondary Stroke Prevention: A Precautionary Tale

Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012

Atrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology

All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER

DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE. Matthew Starr, MD Stroke Attending

CLOSE. Closure of Patent Foramen Ovale, Oral anticoagulants or Antiplatelet Therapy to Prevent Stroke Recurrence

Transcription:

ECG monitoring after ischemic stroke of TIA of unknown source with an insertable monitor? YES Isabelle C Van Gelder University Medical Center Groningen The Netherlands ESC stroke council Prague January 2018

The problem: 25% of ischemic strokes is cryptogenic cryptogenic stroke imaging echo-doppler specific neurology diagnosis maybe AF maybe AF previous AF LV aneurysm mitral stenosis specific vascular diagnosis ECG monitoring for >24h

ESUS Embolic Stroke of Unknown Sorce (ESUS) occurs frequently Now 24 hour Holter monitoring recommended But detection of AF has important therapeutic implications And not that this is secondary prevention!!

What are the data? High risk patients without clinical AF

Healey for the ASSERT II Investigators Circulation 201f ASSERT II Patients 65 years at cardiology or neurology department but NO history of AF Inclusion if: CHA 2 DS 2 -VASc 2, or OSAS, or BMI > 30 kg/m 2, or And LA 44mm or LAV 58 ml, or NT-proBNP 290 pg/ml Primary endpoint: SCAF 5 min

Healey for the ASSERT II Investigators Circulation 2017 ASSERT II 256 patients Mean age 74 years CHA 2 DS 2 -VASc = 4 LA 47 mm 48% prior stroke or TIA or embolism

Healey for the ASSERT II Investigators Circulation 2017 ASSERT II SCAF occurred in 90 pts :34% per year 39% per year if previous stroke Baseline predictors: Age LA size Blood pressure

REVEAL AF study Reiffel for the REVEAL AF Investigators JAMA Cardiology 2017

REVEAL AF study Reiffel for the REVEAL AF Investigators JAMA Cardiology 2017

REVEAL AF study Reiffel for the REVEAL AF Investigators JAMA Cardiology 2017

REVEAL AF study Reiffel for the REVEAL AF Investigators JAMA Cardiology 2017

What are the data? Thus subclinical AF in patients at risk for stroke is high 30% per year

Monitoring in ESUS patients without known AF What show the studies in ESUS patients who are monitored for > 24 hours?

Long term monitoring in cryptogenic stroke EMBRACE-AF GLADSTONE for the EMBRACE-AF Investigators New Engl J Med 2014 572 patients > 55 years with cryptogenic stroke No prior AF Randomized to 30 days event triggered monitoring (irregular rhythm) versus repeat 24 hour Holter monitoring Primary outcome: SCAF > 30 seconds detected during first 6 months

Long term monitoring in cryptogenic stroke EMBRACE-AF GLADSTONE for the EMBRACE-AF Investigators New Engl J Med 2014

Long term monitoring in cryptogenic stroke EMBRACE-AF GLADSTONE for the EMBRACE-AF Investigators New Engl J Med 2014 Repeat Holter (n=285) 30-day Monitor (n=287) p-value Absolute Detection Difference (95% CI) NNS Primary Outcome AF 30 seconds 3% 16% <0.001 13% (9%-18%) 8 Secondary Outcomes AF 2.5 min 2% 10% <0.001 8% (4%-12%) 13 Any AF 4% 20% <0.001 16% (10%- 21%) 6

Long term ILR in ESUS patients CRYSTAL-AF Sanna for the CRYSTAL-AF Investigators New Engl J Med 2014 441 patients > 40 years with ESUS No prior AF Randomized to implantable loop recorder versus routine clinical care Primary endpoint: AF > 30 seconds detected < 6 months

Long term monitoring in cryptogenic stroke CRYSTAL-AF Sanna for the CRYSTAL-AF Investigators New Engl J Med 2014 AF > 30 seconds Median time to detection 41 days Rate of detection in ICM arm was 30.0% vs 3.0% in control arm after 36 months

Conclusion ECG monitoring after ischemic stroke/ TIA of unknown source with an insertable monitor? YES

Sanna for the CRYSTAL-AF Investigators New Engl J Med 2014 Safety and benefit of ILR Infection: 1.4% ILR remained inserted in 97% at 1 year Number needed to implant to detect 1 st episode AF 14 for 6 months, 4 for 36 months

Camm et al. ESC focussed update AF guidelines Eur Heart J 2012 High risk patients AF can also occur asymptomatic: silent AF

And cryptogenic ischemic strokes may be associated with AF 123 patients with ESUS using ILR AF in 23 patients (20%) First detection after 4 months Israel Thrombosis Hemostasis 2017

Healey New Engl J Med 2012 ASSERT Study Risk of ischemic stroke or embolism in SCAF 2580 patients with hypertension, > 65 yrs no AF, pacemaker or ICD Follow-up: 2.5 years Subclinical AF: > 6 min > 190 bpm

Temporal disconnect monitoring VKA therapy stroke Brambatti for the ASSERT Investigators Circulation 2014 Parekh et al. Circ 2006

Brambatti for the ASSERT Investigators Circulation 2014 AF: mechanism or marker for stroke? SCAF episodes are associated with AF but only a minority had SCAF in the month before their stroke

Continuous rhythm monitoring RACE V Medtronic Advisa Pacemaker Medtronic Reveal LINQ CareLink system

65 year old female Symptomatic atrial fibrillation Risk factor for AF hypertension Near collaps ~19.15 h

35 year old male Symptomatic atrial fibrillation Obesity, BMI 31, no other risk factors

Conclusions Remote monitoring of patients with implantable cardiac devices has benefits both for patients and physicians Earlier detection of clinically relevant events not limited to SCAF Probable a reduction of health care costs and consumption However, an issue is how to handle all those data efficiently The FOCUSON TM monitoring and triaging center may help to manage an adequate handling of all transmitted ECG data And it may potentially help to improve cardiovascular outcome

Thank you for your attention atrialfibrillationresearch.nl